Cargando…

Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study

Relapsed/refractory acute myeloid leukemia (RR-AML) are important types of hematological malignancy for which no effective salvage chemotherapy has been approved. The main purpose of this study was to determine the effectiveness of adding Bortezomib to salvage chemotherapy protocol in RR-AML patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghadiany, Mojtaba, Tabarraei, Mehdi, Varaminian, Beehnaz, Salari, Sina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842590/
https://www.ncbi.nlm.nih.gov/pubmed/35194425
http://dx.doi.org/10.22037/ijpr.2021.115475.15409
_version_ 1784651076882923520
author Ghadiany, Mojtaba
Tabarraei, Mehdi
Varaminian, Beehnaz
Salari, Sina
author_facet Ghadiany, Mojtaba
Tabarraei, Mehdi
Varaminian, Beehnaz
Salari, Sina
author_sort Ghadiany, Mojtaba
collection PubMed
description Relapsed/refractory acute myeloid leukemia (RR-AML) are important types of hematological malignancy for which no effective salvage chemotherapy has been approved. The main purpose of this study was to determine the effectiveness of adding Bortezomib to salvage chemotherapy protocol in RR-AML patients. In this prospective non-interventional study, 40 consecutive patients with RR-AML attending Taleghani Hospital who underwent salvage therapy, were enrolled and subdivided into salvage chemotherapy plus Bortezomib and salvage chemotherapy without Bortezomib and the therapeutic response, adverse effects, and survival among them were determined. The results in this study demonstrated that complete response was present in 30% and 25% in Bortezomib group and the other group, respectively and the partial response was seen in 35% and 50% and no response was present in 35% and 25%, respectively (P = 0.621). Furthermore, in each group, 15% had a side effect (P = 1.000). Mean survival was 8.2 and 7.1 in Bortezomib and the other group, respectively (P = 0.275). Based on the obtained results, it may be concluded that adding Bortezomib to salvage chemotherapy is feasible in RR-AML patients. For evaluation of efficacy further study is recommended.
format Online
Article
Text
id pubmed-8842590
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-88425902022-02-21 Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study Ghadiany, Mojtaba Tabarraei, Mehdi Varaminian, Beehnaz Salari, Sina Iran J Pharm Res Original Article Relapsed/refractory acute myeloid leukemia (RR-AML) are important types of hematological malignancy for which no effective salvage chemotherapy has been approved. The main purpose of this study was to determine the effectiveness of adding Bortezomib to salvage chemotherapy protocol in RR-AML patients. In this prospective non-interventional study, 40 consecutive patients with RR-AML attending Taleghani Hospital who underwent salvage therapy, were enrolled and subdivided into salvage chemotherapy plus Bortezomib and salvage chemotherapy without Bortezomib and the therapeutic response, adverse effects, and survival among them were determined. The results in this study demonstrated that complete response was present in 30% and 25% in Bortezomib group and the other group, respectively and the partial response was seen in 35% and 50% and no response was present in 35% and 25%, respectively (P = 0.621). Furthermore, in each group, 15% had a side effect (P = 1.000). Mean survival was 8.2 and 7.1 in Bortezomib and the other group, respectively (P = 0.275). Based on the obtained results, it may be concluded that adding Bortezomib to salvage chemotherapy is feasible in RR-AML patients. For evaluation of efficacy further study is recommended. Shaheed Beheshti University of Medical Sciences 2021 /pmc/articles/PMC8842590/ /pubmed/35194425 http://dx.doi.org/10.22037/ijpr.2021.115475.15409 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ghadiany, Mojtaba
Tabarraei, Mehdi
Varaminian, Beehnaz
Salari, Sina
Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study
title Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study
title_full Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study
title_fullStr Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study
title_full_unstemmed Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study
title_short Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study
title_sort efficacy of adding bortezomib to salvage chemotherapy in relapsed/refractory acute myeloid leukemia a prospective non-interventional study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842590/
https://www.ncbi.nlm.nih.gov/pubmed/35194425
http://dx.doi.org/10.22037/ijpr.2021.115475.15409
work_keys_str_mv AT ghadianymojtaba efficacyofaddingbortezomibtosalvagechemotherapyinrelapsedrefractoryacutemyeloidleukemiaaprospectivenoninterventionalstudy
AT tabarraeimehdi efficacyofaddingbortezomibtosalvagechemotherapyinrelapsedrefractoryacutemyeloidleukemiaaprospectivenoninterventionalstudy
AT varaminianbeehnaz efficacyofaddingbortezomibtosalvagechemotherapyinrelapsedrefractoryacutemyeloidleukemiaaprospectivenoninterventionalstudy
AT salarisina efficacyofaddingbortezomibtosalvagechemotherapyinrelapsedrefractoryacutemyeloidleukemiaaprospectivenoninterventionalstudy